Avadel Pharmaceuticals
AVDL
AVDL was delisted on the 11th of February, 2026.
159 hedge funds and large institutions have $836M invested in Avadel Pharmaceuticals in 2024 Q4 according to their latest regulatory filings, with 24 funds opening new positions, 69 increasing their positions, 39 reducing their positions, and 40 closing their positions.
104% more call options, than puts
Call options by funds: $26.4M | Put options by funds: $12.9M
77% more repeat investments, than reductions
Existing positions increased: 69 | Existing positions reduced: 39
4.96% more ownership
Funds ownership: 77.55% → 82.51% (+5%)
10% less funds holding
Funds holding: 176 → 159 (-17)
13% less funds holding in top 10
Funds holding in top 10: 8 → 7 (-1)
15% less capital invested
Capital invested by funds: $979M → $836M (-$143M)
40% less first-time investments, than exits
New positions opened: 24 | Existing positions closed: 40
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TSC
Two Seas Capital
Rye,
New York
|
+$24.8M |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$11.7M |
| 3 |
BIP
Brandes Investment Partners
La Jolla,
California
|
+$9.7M |
| 4 |
Janus Henderson Group
London,
United Kingdom
|
+$9.15M |
| 5 |
B
Braidwell
Stamford,
Connecticut
|
+$8.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WP
Woodline Partners
San Francisco,
California
|
-$14.4M |
| 2 |
PCM
Penn Capital Management
Philadelphia,
Pennsylvania
|
-$8M |
| 3 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$6.41M |
| 4 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
-$5.1M |
| 5 |
CCM
Cutter Capital Management
New York
|
-$5.05M |
AVDL Hedge Fund Activity: Q4 2024 in Review
159 of the 7,599 institutional investors tracked by Wall St. Rank reported a position in Avadel Pharmaceuticals (AVDL) for Q4 2024, worth a combined $836M — down 15% from $979M a quarter earlier.
Sellers outnumbered buyers: 40 funds closed out of AVDL and 24 opened new positions — a net loss of 16 holders — while 39 trimmed existing stakes and 69 added.
The largest buyer was Two Seas Capital, adding an estimated $24.8M. The largest seller was Woodline Partners, cutting an estimated $14.4M.
- 159 institutional investors held Avadel Pharmaceuticals (AVDL) as of Q4 2024, down from 176 in Q3 2024.
- Funds reported $836M of Avadel Pharmaceuticals stock for Q4 2024, down 15% quarter-over-quarter.
- 24 funds opened new Avadel Pharmaceuticals positions in Q4 2024 and 40 closed out, a net change of -16 holders.
- The largest Avadel Pharmaceuticals buyer in Q4 2024 was Two Seas Capital, an estimated $24.8M added.
- The largest Avadel Pharmaceuticals seller in Q4 2024 was Woodline Partners, an estimated $14.4M sold.
Based on aggregated 13F filings for Q4 2024.